Fennec Pharmaceuticals Inc.
PEDMARK
cisplatin-induced hearing loss
Resolved
156days ago
Phase 2 readout · Feb 1, 2026
What's at stake
Phase 2 trial results for PEDMARK in cisplatin-induced hearing loss are due Feb 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In February 2026, Fennec announced it presented the first new data since the pivotal clinical program at the 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS).”